全文获取类型
收费全文 | 246051篇 |
免费 | 31500篇 |
国内免费 | 8058篇 |
专业分类
耳鼻咽喉 | 1878篇 |
儿科学 | 2425篇 |
妇产科学 | 6070篇 |
基础医学 | 19054篇 |
口腔科学 | 3047篇 |
临床医学 | 21521篇 |
内科学 | 28884篇 |
皮肤病学 | 1675篇 |
神经病学 | 1481篇 |
特种医学 | 6436篇 |
外国民族医学 | 262篇 |
外科学 | 30422篇 |
综合类 | 32608篇 |
现状与发展 | 46篇 |
一般理论 | 3篇 |
预防医学 | 15637篇 |
眼科学 | 275篇 |
药学 | 19924篇 |
144篇 | |
中国医学 | 6268篇 |
肿瘤学 | 87549篇 |
出版年
2024年 | 511篇 |
2023年 | 4723篇 |
2022年 | 7769篇 |
2021年 | 13040篇 |
2020年 | 11839篇 |
2019年 | 10823篇 |
2018年 | 10481篇 |
2017年 | 10845篇 |
2016年 | 11803篇 |
2015年 | 13569篇 |
2014年 | 19878篇 |
2013年 | 20308篇 |
2012年 | 16629篇 |
2011年 | 16931篇 |
2010年 | 12417篇 |
2009年 | 12427篇 |
2008年 | 12823篇 |
2007年 | 12078篇 |
2006年 | 10596篇 |
2005年 | 8695篇 |
2004年 | 7236篇 |
2003年 | 5901篇 |
2002年 | 4931篇 |
2001年 | 4511篇 |
2000年 | 3705篇 |
1999年 | 3160篇 |
1998年 | 2630篇 |
1997年 | 2330篇 |
1996年 | 1889篇 |
1995年 | 1729篇 |
1994年 | 1455篇 |
1993年 | 1126篇 |
1992年 | 998篇 |
1991年 | 899篇 |
1990年 | 662篇 |
1989年 | 620篇 |
1988年 | 492篇 |
1987年 | 459篇 |
1986年 | 336篇 |
1985年 | 469篇 |
1984年 | 360篇 |
1983年 | 237篇 |
1982年 | 267篇 |
1981年 | 238篇 |
1980年 | 210篇 |
1979年 | 146篇 |
1978年 | 96篇 |
1977年 | 93篇 |
1976年 | 86篇 |
1975年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
目的:研究临床路径在大肠癌手术患者中的应用效果。方法:选择广东省江门地区某三甲医院2006年7月至2007年12月间实施临床路径的大肠癌手术患者192例作为实验组,对照组选择该院2005年1月至2006年6月间未实施临床路径按常规模式实施的大肠癌手术患者174例,比较两组患者在住院日、住院费用、患者满意度等方面有无差异性。结果:实验组患者的平均住院日、住院费用等方面明显低于对照组(P<0.01),患者满意度优于对照组(P<0.01)。结论:按临床路径对大肠癌手术患者实施围手术期诊疗护理计划,可减少患者平均住院日,降低住院费用,提高医疗护理服务质量及患者满意度,为进一步扩大临床路径的临床应用范围提供实验数据。 相似文献
992.
G Lunardi M O Vannozzi C Bighin L Del Mastro I Stevani G Schettini M Venturini 《Annals of oncology》2003,14(8):1222-1226
BACKGROUND: Anthracycline cardiotoxicity is increased by the contemporaneous administration of trastuzumab. The mechanism by which it occurs is as yet unknown. The aim of this study was to evaluate whether trastuzumab modifies the pharmacokinetics of epirubicin and its metabolites. PATIENTS AND METHODS: Women with HER2-positive metastatic breast cancer were treated with epirubicin 75 mg/m(2) i.v. bolus followed by docetaxel 75 mg/m(2) in a 1-h infusion, every 3 weeks for six cycles, and trastuzumab (once at 4 mg/m(2), then 2 mg/m(2) weekly thereafter) in a 30-min infusion. Epirubicin pharmacokinetic data of seven patients were evaluated at the first cycle of therapy (baseline, with trastuzumab administered 24 h after epirubicin), and at the sixth cycle (i.e. 15 weeks after baseline, with trastuzumab administered immediately before epirubicin). RESULTS: No pharmacokinetic change in the parent compound epirubicin was detected. The area under the plasma concentration-time curve (AUC(0-24 h)) was 1230 +/- 318 [mean +/- standard deviation (SD)] at the first cycle and 1287 +/- 385 h. micro g/l at the sixth. The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively). Pharmacokinetic data of epirubicin metabolites evaluated at the first and sixth cycle of chemotherapy were superimposable without any statistical difference. CONCLUSION: Enhanced anthracycline cardiotoxicity related to trastuzumab administration was not linked to pharmacokinetic interferences with epirubicin and its metabolites. 相似文献
993.
目的探讨危重病患者是否存在高胰岛素血症、胰岛素抵抗(IR)及与肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)的关系.方法测定危重病患者123例和对照组30例的空腹血糖(FBG)、空腹胰岛素(FINS)、TNF-α、IL-6的水平,并计算胰岛素敏感性指数(IAI),以评估危重病患者IR的严重程度,并分析各参数之间的相关性.结果危重病组与对照组的IAi分别为-1.95±0.38和-1.5±0.29,两者差异显著(P<0.01).危重病按病因分组后各组IAI相比无显著差异(P>0.05).IAI与危重病严重程度、TNF-α及IL-6的直线回归分析,直线关系r分别为0.86,-0.89,-0.87,差异有显著性(P<0.01).结论危重病患者存在高胰岛素血症及IR.IR的程度与危重病程度、TNF-α、IL-6的水平有显著相关性.危重病患者的IR与TNF-α的升高有关,提示IAI可作为危重病患者病情严重程度的预测指标. 相似文献
994.
斯奇康联合丝裂霉素顺铂胸腔内注射治疗肺癌恶性胸水的疗效观察 总被引:2,自引:0,他引:2
目的 探讨斯奇康联合丝裂霉素、顺铂胸腔内注射治疗肺癌恶性胸水的有效性和安全性。方法 对我科1999年以来确诊为肺癌恶性胸水的 5 3例患者 ,随机分为斯奇康组 ( 2 7例 )和对照组 ( 2 6例 ) ,进行胸腔内注药 ,观察治疗的有效率、Karnofsky评分及不良反应。结果 斯奇康组与对照组治疗有效率分别为 88 8%和 5 3 9%,两组比较有显著性差异 (P <0 0 1) ;两组治疗后生存质量均有改善 ,但Karnofsky评分 70分以上治疗组为 66 7%,对照组为 3 0 8%,两组比较差异显著 (P <0 0 1) ;两组均出现不同程度的白细胞、血小板减少 ,但治疗组与对照组相比反应明显较轻 ,有显著性差异 (P <0 0 5 )。结论 斯奇康联合丝裂霉素、顺铂胸腔内注射治疗肺癌恶性胸水疗效较好 ,毒副反应较轻。 相似文献
995.
Olivier Chataigner Elie Fadel Bedrettin Yildizeli Abdallah Achir Sacha Mussot Dominique Fabre Olaf Mercier Philippe G. Dartevelle 《European journal of cardio-thoracic surgery》2008,33(5):837-843
Objective: To identify factors that affect operative mortality and morbidity and long-term survival after completion pneumonectomy. Methods: We retrospectively reviewed the charts of consecutive patients who underwent completion pneumonectomy at our cardiothoracic surgery department from January 1996 to December 2005. Results: We identified 69 patients, who accounted for 17.8% of all pneumonectomies during the study period; 22 had benign disease and 47 malignant disease (second primary lung cancer, n = 19; local recurrence, n = 17; or metastasis, n = 11). There were 50 males and 19 females with a mean age of 60 years (range, 29–80 years). Postoperative mortality was 12% and postoperative morbidity 41%. Factors associated with postoperative mortality included obesity (p = 0.005), coronary artery disease (p = 0.03), removal of the right lung (p = 0.02), advanced age (p = 0.02), and renal failure (p < 0.0001). Preoperative renal failure was the only significant risk factor for mortality by multivariate analysis (p = 0.036). Bronchopleural fistula developed in seven patients (10%), with risk factors being removal of the right lung (p = 0.04) and mechanical stump closure (p = 0.03). Overall survival was 65% after 3 years and 46% after 5 years. Long-term survival was not affected by the reason for completion pneumonectomy. Conclusion: Although long-term survival was acceptable, postoperative mortality and morbidity rates remained high, confirming the reputation of completion pneumonectomy as a challenging procedure. Significant comorbidities and removal of the right lung were the main risk factors for postoperative mortality. Improved patient selection and better management of preoperative renal failure may improve the postoperative outcomes of this procedure, which offers a chance for prolonged survival. 相似文献
996.
997.
A. Keshava P. H. Chapuis C. Chan† B. P. C. Lin† E. L. Bokey O. F. Dent 《Colorectal disease》2007,9(7):609-618
OBJECTIVE: To determine whether the presence of tumour at a free serosal surface was independently associated with pelvic recurrence or survival in patients who had a resection for clinicopathological stage B or stage C rectal cancer and who had not received adjuvant therapy. METHOD: Data were drawn from a comprehensive, prospective hospital registry of all resections for rectal cancer from January 1971 to December 1998 with follow up to December 2003. Statistical analysis employed the chi(2) test or Fisher's exact probability, Kaplan-Meier estimation and proportional hazards regression, with a significance level of < or =0.05 and 95% confidence intervals (CI). RESULTS: In 665 patients with stages B or C tumour, 35 (5.3%; CI 3.7-7.2%) had tumour at a free serosal surface. These comprised 6/332 (1.8%; CI 0.8-3.7%) patients with stage B tumour and 29/333 (8.7%; CI 6.1-12.2%) with stage C tumour. After adjustment for other relevant variables, involvement of a free serosal surface was significantly associated with pelvic recurrence [hazard ratio (HR) 2.7; CI 1.3-5.5] and diminished survival (HR 1.6; CI 1.1-2.4) but not with systemic (only) recurrence. CONCLUSION: This study has confirmed that direct tumour spread to a free serosal surface independently predicts pelvic recurrence and diminished survival after resection of clinicopathological stage B and C rectal cancer. This feature should always be sought by the pathologist and reported when present, and noted by the surgeon and oncologist. Serosal involvement should be evaluated further for its utility in selecting patients for adjuvant therapy. 相似文献
998.
999.
目的分析累及移行带前列腺癌的临床特征,提高移行带前列腺癌的诊断率。方法回顾我院收治的77例前列腺癌患者,一组44例仅限于外周带;另一组33例已累及移行带。分析两组的临床表现、直肠指检、移行指数、前列腺移行带特异性抗原密度、前列腺特异性抗原、经直肠前列腺超声以及前列腺穿刺活检。结果两组患者的年龄、排尿期和储尿期症状、直肠指检阳性率、移行指数、前列腺移行带特异性抗原密度、前列腺特异性抗原以及病理分级没有显著性差异。移行带肿瘤存在泌尿系转移的风险。经直肠超声为移行带可疑病灶的定位提供了重要的参考,而对可疑病灶穿刺活检则能提高累及移行带前列腺癌的诊断率。结论经直肠超声行移行带可疑病灶的穿刺活检是诊断累及移行带前列腺癌的有效手段。 相似文献
1000.
Richard A. Perugini Steven H. Quarfordt Stephen Baker Donald R. Czerniach Demetrius E. M. Litwin John J. Kelly 《Journal of gastrointestinal surgery》2007,11(9):1083-1090
Introduction Obese individuals may have normal insulin–glucose homeostasis, insulin resistance, or diabetes mellitus. Whereas gastric bypass
cures insulin resistance and diabetes mellitus, its effects on normal physiology have not been described. We studied insulin
resistance and β-cell function for patients undergoing gastric bypass.
Methods One hundred thirty-eight patients undergoing gastric bypass had fasting insulin and glucose levels drawn on days 0, 12, 40,
180, and 365. Thirty-one (22%) patients with diabetes mellitus were excluded from this analysis. Homeostatic model of assessment
was used to estimate insulin resistance, insulin sensitivity, and β-cell function. Based on this model, patients were categorized
as high insulin resistance if their insulin resistance was >2.3.
Results Body mass index did not correlate with insulin resistance. Forty-seven (34%) patients were categorized as high insulin resistance.
Correction of insulin resistance for this group occurred by 12 days postoperatively. Sixty (43%) patients were categorized
as low insulin resistance. They demonstrated an increase of β-cell function by 12 days postoperatively, which returned to
baseline by 6 months. At 1 year postoperatively, the low insulin resistance group had significantly higher β-cell function
per degree of insulin sensitivity.
Conclusions Adipose mass alone cannot explain insulin resistance. Severely obese individuals can be categorized by degree of insulin resistance,
and the effect of gastric bypass depends upon this preoperative physiology. 相似文献